Chemotherapy for advanced gastric cancer: future perspective in Japan.

about

Chemotherapy for advanced gastric cancer: future perspective in Japan.

Item

http://www.wikidata.org/entity/Q38815071

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Chemotherapy for advanced gastric cancer: future perspective in Japan.

@en

type

Item

label

Chemotherapy for advanced gastric cancer: future perspective in Japan.

@en

prefLabel

Chemotherapy for advanced gastric cancer: future perspective in Japan.

@en

P1476

Chemotherapy for advanced gastric cancer: future perspective in Japan.

@en

P2093

Kohei Shitara

http://www.w3.org/2001/XMLSchema#string

P2860

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.

Comprehensive molecular characterization of gastric adenocarcinoma

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.

P2888

s10120-016-0648-7

P304

102-110

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10120-016-0648-7

http://www.w3.org/2001/XMLSchema#string

P433

Suppl 1

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-10-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1046021282

http://www.w3.org/2001/XMLSchema#string

P698

27699493

http://www.w3.org/2001/XMLSchema#string